Livzon Pharmaceutical Group (1513) Stock Statistics & Valuation Metrics

Livzon Pharmaceutical Group has a market cap or net worth of HKD 28.36B. The enterprise value is HKD 17.84B.

Market Cap

HKD 28.36B

Enterprise Value

HKD 17.84B

Livzon Pharmaceutical Group has 299,807,130 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

299,807,130

Owned by Insiders

―

Owned by Institutions

5.95%

Livzon Pharmaceutical Group’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 12.50%.

Return on Equity (ROE)

0.15

Return on Assets (ROA)

0.08

Return on Invested Capital (ROIC)

12.50%

Return on Capital Employed (ROCE)

0.18

Revenue Per Employee

1.35M

Profits Per Employee

227.89K

Employee Count

8,878

Asset Turnover

0.50

Inventory Turnover

2.62

The current PE Ratio of Livzon Pharmaceutical Group is 17.61. Livzon Pharmaceutical Group’s PEG ratio is -0.65.

PE Ratio

17.61

PS Ratio

2.36

PB Ratio

2.10

Price to FCF

8.74

Price to Operating Cash Flow

8.62

PEG Ratio

-0.65

In the last 12 months, Livzon Pharmaceutical Group had revenue of 12.02B and earned 2.02B in profits. Earnings per share was 2.27.

Revenue

12.02B

Gross Profit

7.92B

Operating Income

2.95B

Pretax Income

2.86B

Net Income

2.02B

EBITDA

3.10B

Earnings Per Share (EPS)

2.27

In the last 12 months, operating cash flow was 3.20B and capital expenditures -414.85M, giving a free cash flow of 2.79B billion.

Operating Cash Flow

3.20B

Free Cash Flow

2.79B

Free Cash Flow per Share

3.11

Livzon Pharmaceutical Group pays an annual dividend of HKD 1.64, resulting in a dividend yield of 6.43%

Dividend Per Share

HKD 1.64

Dividend Yield

6.43%

Payout Ratio

65.63%

Free Cash Flow Yield

11.44%

Earnings Yield

5.69%

Beta

0.70

52-Week Price Change

-24.09%

50-Day Moving Average

20.58

200-Day Moving Average

23.61

Relative Strength Index (RSI)

71.00

Average Volume (3m)

1.66M

Livzon Pharmaceutical Group upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 23, 2026

Next Earnings Date

Mar 31, 2027

Ex-Dividend Date

Jun 16, 2026

Livzon Pharmaceutical Group as a current ratio of 2.23, with Debt / Equity ratio of 27.69%

Current Ratio

2.23

Quick Ratio

2.02

Debt to Market Cap

0.17

Net Debt to EBITDA

-1.76

Interest Coverage Ratio

48.99

In the past 12 months, Livzon Pharmaceutical Group has paid 451.01M in taxes.

Income Tax

451.01M

Effective Tax Rate

0.16

Livzon Pharmaceutical Group EV to EBITDA ratio is 9.01, with an EV/FCF ratio of 7.64.

EV to Sales

2.06

EV to EBITDA

9.01

EV to Free Cash Flow

7.64

EV to Operating Cash Flow

6.65

Livzon Pharmaceutical Group has HKD 7.31B in cash and marketable securities with HKD 4.20B in debt, giving a net cash position of HKD 3.11B billion.

Cash & Marketable Securities

HKD 7.31B

Total Debt

HKD 4.20B

Net Cash

HKD 3.11B

Net Cash Per Share

HKD 10.38

Tangible Book Value Per Share

HKD 13.70

Gross margin is 60.53%, with operating margin of 19.25%, and net profit margin of 15.23%.

Gross Margin

60.53%

Operating Margin

19.25%

Pretax Margin

21.50%

Net Profit Margin

15.23%

EBITDA Margin

22.91%

EBIT Margin

19.83%

The average price target for Livzon Pharmaceutical Group is HKD 34.26, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

HKD 34.26

Price Target Upside

41.57% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

-9.56%

EPS Growth Forecast

-23.22%

Smart Score

5

AI Score

74